Plain-English translation of NCT06138028 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a combination treatment for advanced esophageal squamous cell carcinoma (a type of esophageal cancer). The treatment combines sintilimab (an immune-boosting medication that helps your body fight cancer) with chemotherapy drugs, followed by radiation therapy to target remaining tumors. Researchers want to see if this three-part approach is more effective than standard treatments alone.
Advanced esophageal cancer is very serious and current treatments don't work well enough for many patients. This trial is exploring whether adding this medication to help the immune system recognize and attack cancer cells might improve survival and help more people benefit from treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the immune-boosting medication along with chemotherapy drugs as an infusion over 4 treatment cycles. After that, you will undergo radiation therapy to target any remaining tumors while continuing to receive the medication for maintenance over 13 additional cycles. You will need regular visits to the hospital or clinic for treatment administration, blood tests, and imaging scans to monitor how well the treatment is working and watch for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China